Bowman Brent R
Known title: Chief Financial OfficerCIK: 0001816980
Associated companies
Transaction History
| VEEV | ▲ Buy | Option Exercise | 1,296 | $0 | 4/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 463 | $107K | 4/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,295 | $0 | 1/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 508 | $98K | 1/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,296 | $0 | 10/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 449 | $91K | 10/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 449 | $89K | 7/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,296 | $0 | 7/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,176 | $0 | 4/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 407 | $75K | 4/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,177 | $0 | 1/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 467 | $75K | 1/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,176 | $0 | 10/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 407 | $67K | 10/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,177 | $0 | 7/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 408 | $83K | 7/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 545 | $0 | 4/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 545 | $0 | 1/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 224 | $57K | 1/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 545 | $0 | 10/1/2021 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 189 | $54K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus
Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.